Trius Therapeutics (TSRX) I bought $TSRX trade call target = $6 + Trius is expecting top-line data from its 2nd Phase III trial of Tedizolid (TR-701) vs. Linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI)…
Trius Therapeutics (TSRX) I bought $TSRX trade call target = $6 + Trius is expecting top-line data from its 2nd Phase III trial of Tedizolid (TR-701) vs. Linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI)…